Minerva Neurosciences (NERV) Common Equity (2013 - 2026)
Minerva Neurosciences (NERV) posted Common Equity of -$254.0 million for Q1 2026, down 80.47% on a QoQ basis from -$140.7 million in Q4 2025, and down 771.44% year-over-year from $37.8 million in Q1 2025.
Minerva Neurosciences (NERV) Common Equity (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Common Equity history runs 14 years deep, the most recent figure standing at -$254.0 million for Q1 2026.
- Quarterly Common Equity fell 771.44% year-over-year to -$254.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$254.0 million (down 771.44% YoY) and the FY2025 annual result came in at -$140.7 million, down 447.8% from the prior year.
- Common Equity was -$254.0 million for Q1 2026 at Minerva Neurosciences, down from -$140.7 million in the prior quarter.
- Across five years, Common Equity topped out at -$736130.0 in Q1 2022 and bottomed at -$254.0 million in Q1 2026.
- A 5-year average of -$44.1 million and a median of -$26.6 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity plunged 3515.96% — and 2025, when it gained 27.83%.
- Minerva Neurosciences' Common Equity stood at -$20.0 million in 2022, then slumped by 42.12% to -$28.5 million in 2023, then increased by 9.71% to -$25.7 million in 2024, then slumped by 447.8% to -$140.7 million in 2025, then sank by 80.47% to -$254.0 million in 2026.
- Business Quant data shows NERV's Common Equity at -$254.0 million in Q1 2026, -$140.7 million in Q4 2025, and -$34.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -98.34 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.76 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.36 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.50 Bn |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - | -254.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -254.01 Mn |
| Dec 31, 2025 | -140.75 Mn |
| Sep 30, 2025 | -34.58 Mn |
| Jun 30, 2025 | -32.11 Mn |
| Mar 31, 2025 | -29.15 Mn |
| Dec 31, 2024 | -25.69 Mn |
| Sep 30, 2024 | -21.67 Mn |
| Jun 30, 2024 | -44.49 Mn |
| Mar 31, 2024 | -36.59 Mn |
| Dec 31, 2023 | -28.46 Mn |
| Sep 30, 2023 | -20.05 Mn |
| Jun 30, 2023 | -12.51 Mn |
| Mar 31, 2023 | -26.62 Mn |
| Dec 31, 2022 | -20.02 Mn |
| Sep 30, 2022 | -14.25 Mn |
| Jun 30, 2022 | -8.38 Mn |
| Mar 31, 2022 | -736,130.00 |
| Dec 31, 2021 | 7.98 Mn |
| Sep 30, 2021 | 28.08 Mn |
| Jun 30, 2021 | 36.17 Mn |